Blood cancers

A new era of precision medicine in CLL: Dr Phillip Thompson


In this two-part podcast, haematologist and clinical researcher Dr Phillip Thompson talks about the exciting changes taking place in treatment of chronic lymphocytic leukaemia, where an expanding array of new agents means we are moving into an era of precision medicine for CLL patients in both front line and relapse treatment.

Dr Thompson trained at St Vincent’s Hospital, Melbourne and is now Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston. He has a particular interest in developing MRD-directed therapeutic strategies in CLL and Richter’s transformation.

Part 1: A new era of precision medicine in CLL (front-line treatment)
Part 2: The changing therapeutic landscape for R/R CLL

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from www.janssen.com.au/imbruvica_PI).

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic